Depot shot for pain in women with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests if a hormone shot (depot medroxyprogesterone acetate) can help reduce pain episodes in women with sickle cell disease. It aims to see if the shot improves pain and markers of inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 50 years old.
- Diagnosed with sickle cell disease (types SS, SC, or sickle beta zero/plus thalassemia).
- Had at least 1 painful crisis per month on average in the last 6 months.
- Had 1 to 10 hospital or clinic visits for pain in the past year.
- Not currently using hormonal birth control; must stop all hormonal birth control for at least 1 month before starting the study (or 4 months if you recently had the depot shot).
- Regular menstrual cycles (21 to 35 days long) when not on hormonal birth control.
- Stable doses of sickle cell medications (like hydroxyurea) for at least 6 months.
- No history of blood clots, stroke, or chronic inflammatory conditions like lupus.
- Not currently using crizanlizumab, voxelotor, or chronic blood transfusions.
- Not pregnant or breastfeeding, and no pregnancy in the last 6 months.
- No polycystic ovary syndrome or irregular periods.
- Blood pressure below 160/100 at the screening visit.
- Access to a device with text messaging and able to read English.
- Willing to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new gene therapy to the standard care for people with severe sickle cell disease. It aims to see if the gene therapy is better at reducing painful crises and complications.
This study tests whether a low-dose of ketamine (a pain medicine) can help children and young adults with sickle cell disease who are in a pain crisis. It aims to provide better pain relief while avoiding some side effects of standard painkillers.
This trial tests whether a numbing medicine (lidocaine) given through a vein can help reduce the amount of strong painkillers (morphine or oxycodone) needed for a sickle cell pain crisis or acute chest syndrome. It aims to ease pain and possibly lower side effects from opioids.
This study tests whether a low dose of ketamine, a pain medicine, can safely reduce pain during a sickle cell crisis in the emergency department. It aims to provide quicker pain relief for people with sickle cell disease.
This study tests whether pressing certain points on your body (acupressure) can help reduce pain from sickle cell disease. You'll learn to do it yourself at home every other day for 5 weeks.
This study tests an investigational oral pill called etavopivat that may help reduce pain crises in people with sickle cell disease. You may qualify if you have frequent pain crises and are not on regular blood transfusions.
Hear when a new Vaso-Occlusive Pain Episode in Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.